74 related articles for article (PubMed ID: 22644853)
1. Solid state of a new PDE-5 inhibitor DA-8159: characterization, dissolution, transformation.
Ryu JY; Sohn YT
Arch Pharm Res; 2012 May; 35(5):861-6. PubMed ID: 22644853
[TBL] [Abstract][Full Text] [Related]
2. Crystal forms of SK-3530.
Song HO; Sohn YT
Arch Pharm Res; 2010 Dec; 33(12):2033-6. PubMed ID: 21191770
[TBL] [Abstract][Full Text] [Related]
3. Solid state of CG-400549, a novel FabI inhibitor: characterization, dissolution, transformation.
Kim BY; Sohn YT
Arch Pharm Res; 2011 May; 34(5):775-9. PubMed ID: 21656363
[TBL] [Abstract][Full Text] [Related]
4. Crystal forms of atorvastatin.
An SG; Sohn YT
Arch Pharm Res; 2009 Jun; 32(6):933-6. PubMed ID: 19557372
[TBL] [Abstract][Full Text] [Related]
5. Crystal forms of naproxen.
Song JS; Sohn YT
Arch Pharm Res; 2011 Jan; 34(1):87-90. PubMed ID: 21468919
[TBL] [Abstract][Full Text] [Related]
6. The influence of amorphization methods on the apparent solubility and dissolution rate of tadalafil.
Wlodarski K; Sawicki W; Paluch KJ; Tajber L; Grembecka M; Hawelek L; Wojnarowska Z; Grzybowska K; Talik E; Paluch M
Eur J Pharm Sci; 2014 Oct; 62():132-40. PubMed ID: 24907679
[TBL] [Abstract][Full Text] [Related]
7. Solid-state form screen of cardiosulfa and its analogues.
Kumar SS; Rana S; Nangia A
Chem Asian J; 2013 Jul; 8(7):1551-68. PubMed ID: 23616361
[TBL] [Abstract][Full Text] [Related]
8. In sight into tadalafil - block copolymer binary solid dispersion: Mechanistic investigation of dissolution enhancement.
Mehanna MM; Motawaa AM; Samaha MW
Int J Pharm; 2010 Dec; 402(1-2):78-88. PubMed ID: 20933589
[TBL] [Abstract][Full Text] [Related]
9. The solid state of rebamipide: preparation, characterization, and dissolution.
Jeon SH; Sohn YT
Arch Pharm Res; 2016 Apr; 39(4):508-515. PubMed ID: 26897596
[TBL] [Abstract][Full Text] [Related]
10. Solid-state characterization of rifampicin samples and its biopharmaceutic relevance.
Agrawal S; Ashokraj Y; Bharatam PV; Pillai O; Panchagnula R
Eur J Pharm Sci; 2004 Jun; 22(2-3):127-44. PubMed ID: 15158898
[TBL] [Abstract][Full Text] [Related]
11. Preparation and characterization of a novel polymorph of indiplon, Form α.
Xu L; Wang J; Xiao B; Yang J; Liu Y; Huang R
Bioorg Med Chem Lett; 2012 Jan; 22(2):963-8. PubMed ID: 22209207
[TBL] [Abstract][Full Text] [Related]
12. Polymorphic form of piroxicam influences the performance of amorphous material prepared by ball-milling.
Naelapää K; Boetker JP; Veski P; Rantanen J; Rades T; Kogermann K
Int J Pharm; 2012 Jun; 429(1-2):69-77. PubMed ID: 22433471
[TBL] [Abstract][Full Text] [Related]
13. Reevaluation of solubility of tolbutamide and polymorphic transformation from Form I to unknown crystal form.
Hasegawa G; Komasaka T; Bando R; Yoshihashi Y; Yonemochi E; Fujii K; Uekusa H; Terada K
Int J Pharm; 2009 Mar; 369(1-2):12-8. PubMed ID: 19026732
[TBL] [Abstract][Full Text] [Related]
14. Study of process induced polymorphic transformations in fluconazole drug.
Desai SR; Dharwadkar SR
Acta Pol Pharm; 2009; 66(2):115-22. PubMed ID: 19719043
[TBL] [Abstract][Full Text] [Related]
15. Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process.
Jun SW; Kim MS; Kim JS; Park HJ; Lee S; Woo JS; Hwang SJ
Eur J Pharm Biopharm; 2007 Jun; 66(3):413-21. PubMed ID: 17240129
[TBL] [Abstract][Full Text] [Related]
16. Recrystallization of fluconazole using the supercritical antisolvent (SAS) process.
Park HJ; Kim MS; Lee S; Kim JS; Woo JS; Park JS; Hwang SJ
Int J Pharm; 2007 Jan; 328(2):152-60. PubMed ID: 16959448
[TBL] [Abstract][Full Text] [Related]
17. The solid-state characterization of fusidic acid.
Gilchrist SE; Letchford K; Burt HM
Int J Pharm; 2012 Jan; 422(1-2):245-53. PubMed ID: 22100514
[TBL] [Abstract][Full Text] [Related]
18. Development of spray-dried co-precipitate of amorphous celecoxib containing storage and compression stabilizers.
Dhumal RS; Shimpi SL; Paradkar AR
Acta Pharm; 2007 Sep; 57(3):287-300. PubMed ID: 17878109
[TBL] [Abstract][Full Text] [Related]
19. Solid-state characterization of an NR2B selective N-methyl d-aspartate (NMDA) antagonist polymorphs.
Kojima T; Sato M; Omura A; Kawai M; Sakai M; Matsuoka Y; Murata Y; Hattori K; Sakemi S; Bordner J; Samardjiev I; Mano T
Int J Pharm; 2008 May; 355(1-2):337-40. PubMed ID: 18242021
[TBL] [Abstract][Full Text] [Related]
20. Solid-state characterization of paclitaxel.
Liggins RT; Hunter WL; Burt HM
J Pharm Sci; 1997 Dec; 86(12):1458-63. PubMed ID: 9423162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
